-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Unicycive Therapeutics, Maintains $22 Price Target

Benzinga·06/30/2026 17:01:33
Listen to the news
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $22 price target.